

The **decision** is in the data.

DecisionDx-SCC is the strongest independent predictor of cutaneous squamous cell carcinoma (SCC) metastasis.¹

97%


of clinicians would change patient management given DecisionDx-SCC results with 2 risk factors.²



Metastatic SCC is deadly and risk is poorly assessed


Clinicopathological risk factors alone are often not specific enough to determine risk-appropriate SCC treatment and further management.

DEATHS PER YEAR IN THE U.S.



2x as many annual SCC deaths in the U.S. as Melanoma^{3,4}



WITH TRADITIONAL STAGING:



1/3 SCC patients under-staged as low risk⁵

Traditional risk factors miss biological risk - A real world case study comparison

Two real world patient cases with similar risk factors and divergent outcomes highlight the limitations of traditional risk factors and staging methods when applying the DecisionDx-SCC gene expression profile test result.⁶



PATIENT	RISK FACTORS	STAGING	DecisionDx ►SCC	OUTCOME
 PATIENT 1: 65-year-old-male SIZE: 1.3 cm	Poorly differentiated	AJCC8: T1: 1 risk factor BWH: T2a: 1 risk factor	CLASS 1 LOW biological risk	Metastasis free for 4 years
 PATIENT 2: 69-year-old-male SIZE: 1.5 cm	Poorly differentiated	AJCC8: T1: 1 risk factor BWH: T2a: 1 risk factor	CLASS 2B HIGH biological risk	Metastasis after 3 months and subsequently died

Biological risk of metastasis with DecisionDx-SCC Results

Tumor biology is a stronger predictor of SCC metastasis risk than traditional risk factors

DecisionDx-SCC gene expression profiling is the strongest independent predictor of SCC metastasis.¹

BIOLOGICAL RISK OF METASTASIS




Independent Validation Study Characteristics: Prospectively designed, multi-center (33) study with archival tissue from 420 patients with known 3-year outcomes.¹

DecisionDx-SCC informs risk appropriate patient management

DecisionDx-SCC results deliver precision patient classification, complementing commonly used traditional risk factors and improving risk assessment in SCC.¹

Patient management considerations include:⁷

- Nodal evaluation: imaging and sentinel lymph node biopsy (SLNB)
- Adjuvant Radiation Therapy (ART)
- Frequency of follow-up and surveillance



*Example use case

Over 2,100 clinicians have ordered DecisionDx-SCC*

*As of June 2022 (6/30) data pull

Intended Use: DecisionDx-SCC is indicated for patients diagnosed with cutaneous squamous cell carcinoma (SCC) and one or more risk factors.^{10,11} DecisionDx-SCC predicts individual metastatic risk to inform risk-appropriate management.^{1,12}

HISTORY AND PHYSICAL EXAMINATION	SURGICAL AND PATHOLOGICAL FINDINGS
Tumor size ≥ 2 cm anywhere on the body	Perineural involvement: <ul style="list-style-type: none"> Large (≥ 0.1 mm) or named nerve involvement Small (< 0.1 mm) in caliber
Tumor location on the head, neck, hands, genitals, feet or pretibial surface (areas H or M)	Poorly differentiated tumor histology
Immunosuppression	Depth: <ul style="list-style-type: none"> Invasion beyond subcutaneous fat Invasion depth ≥ 2 mm Clark level $\geq IV$
Rapidly growing tumor	Aggressive histologic subtype ^a
Tumor with poorly defined borders	Lymphovascular invasion
Tumor at site of prior radiation therapy or chronic inflammation	Desmoplastic SCC
Neurologic symptoms in region of tumor	
DecisionDx-SCC is not intended for use with locally recurrent tumor tissue.	

a) Acantholytic (adenoid), adenosquamous (showing mucin production), or carcinosarcomatous (metaplastic) subtypes¹⁰ (others¹¹ will be considered on a case-by-case basis)

References:

1. Ibrahim et al. *Future Oncology* 2021.
2. Goldberg et al. Presented at Winter Clinical Dermatology. January 14-19, 2022.
3. SEER Data Release 2019.
4. Mansouri B et al. *JAMA Dermatology* 2017.
5. Farberg et al. *Dermatology and Therapy* 2022.
6. Au et al. *Dermatology and Therapy* 2021.
7. Arron et al. *JDD* 2021.
8. Fox et al. *JAAD* 2019.
9. Que et al. *JAAD* 2018.
10. NCCN Guidelines for Squamous Cell Skin Cancer v2.2022.
11. Connolly SM et al. *JAAD* 2012.
12. Wysong et al. *JAAD* 2020.

Patient Access: Castle Biosciences works with all insurance providers, including Medicare, Medicaid, commercial insurers, and the VA, to secure coverage and payment for the DecisionDx-SCC test. Castle will submit insurance claims and manage the insurance billing process on behalf of patients. The company also sponsors an industry-leading Patient Assistance Program with the belief that quality care should not depend on financial considerations. You can get more information about insurance coverage, claims processing, and financial assistance by calling 866-788-9007 and selecting option #3 or by email at reimbursement@castlebiosciences.com.

© 2022 Castle Biosciences Inc, DecisionDx®-SCC is a trademark of Castle Biosciences Inc. DDXSCC-0019v1-082022



Contact us at:
866-788-9007
[CastleBiosciences.com](https://www.CastleBiosciences.com)
CastleTestInfo.com

Laboratory Address:
235 William Pitt Way B1
Pittsburgh, PA 15238

